Chronic constipation: new diagnostic and treatment approaches

被引:21
作者
Lacy, Brian E. [1 ]
Levenick, John M. [1 ]
Crowell, Michael [2 ]
机构
[1] Dartmouth Hitchcock Med Ctr, Sect Gastroenterol & Hepatol, Lebanon, NH 03756 USA
[2] Mayo Clin, Dept Gastroenterol & Hepatol, Scotsdale, AZ USA
来源
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2012年 / 5卷 / 04期
关键词
anorectal manometry; constipation; guanylate cyclase; linaclotide; lubiprostone; plecanitide; prucalopride; Rome criteria; velusetrag; wireless motility capsule; GUANYLATE-CYCLASE-C; IRRITABLE-BOWEL-SYNDROME; QUALITY-OF-LIFE; DIRECT MEDICAL COSTS; INTESTINAL SECRETION; COLONIC TRANSIT; UNITED-STATES; HEALTH-CARE; LINACLOTIDE; DISORDERS;
D O I
10.1177/1756283X12443093
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Chronic constipation is a highly prevalent disorder that affects approximately 15% of the US population. Chronic constipation refers to patients who have had symptoms for more than 6 months. In clinical practice, chronic constipation is often used interchangeably with the term functional constipation. This is best defined using the Rome III criteria, which involves an evaluation of stool frequency in addition to symptoms of straining, feelings of incomplete evacuation, and the need to use manual maneuvers to assist with stool evacuation. Symptoms can be burdensome, leading to a reduction in patients' quality of life. As a national healthcare issue, chronic constipation is also important because it imposes a significant economic impact on the healthcare system. A number of treatment options are currently available, both over-the-counter and by prescription, although not all patients respond to these therapies. This review will focus on new medical treatment options for the management of chronic constipation, and the safety and efficacy of these agents will be reviewed. In addition, the efficacy of new diagnostic tests to evaluate colonic motility and anorectal function are described.
引用
收藏
页码:233 / 247
页数:15
相关论文
共 50 条
  • [31] Linaclotide-a Novel Secretagogue in the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation
    Sharma, Shivani
    Sharma, Tina
    Dhingra, Richa
    Tomar, Prince
    Singh, Sukhminder
    Malhotra, Manav
    Bhardwaj, T. R.
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2013, 13 (11) : 1685 - 1690
  • [32] Constipation in Patients With Chronic Kidney Disease
    Cha, Ra Ri
    Park, Seon-Young
    Camilleri, Michael
    [J]. JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2023, 29 (04) : 428 - 435
  • [33] Constipation - Pathophysiology, Diagnostics, Treatment
    Mueller-Lissner, Stefan
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2019, 144 (16) : 1145 - 1155
  • [34] Plecanatide for the treatment of constipation-predominant irritable bowel syndrome
    Miner, Philip B.
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 14 (02) : 71 - 84
  • [35] Diagnostic of chronic constipation
    Buderus, S
    [J]. MONATSSCHRIFT KINDERHEILKUNDE, 2002, 150 (05) : 587 - +
  • [36] New Options in Constipation Management
    Davis, Mellar
    Gamier, Pamela
    [J]. CURRENT ONCOLOGY REPORTS, 2015, 17 (12)
  • [37] Novel Pharmacological Therapies for Management of Chronic Constipation
    Gonzalez-Martinez, Marina A.
    Ortiz-Olvera, Nayeli X.
    Mendez-Navarro, Jorge
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2014, 48 (01) : 21 - 28
  • [38] Chronic Constipation in the Elderly
    Bouras, Ernest P.
    Tangalos, Eric G.
    [J]. GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2009, 38 (03) : 463 - +
  • [39] Neue Medikamente zur Behandlung der ObstipationNew Drugs for the Treatment of Constipation
    Birgit Adam
    Tobias Liebregts
    Guido Gerken
    [J]. Medizinische Klinik, 2010, 105 (7) : 475 - 478
  • [40] Benefit-Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation
    Miner, Philip B., Jr.
    [J]. DRUG SAFETY, 2019, 42 (05) : 603 - 615